Supernus completes merger with Indivior
Bitget2026/11/02 14:19- Supernus Pharmaceuticals completed its merger with Indivior on Nov. 2, 2026, creating a diversified central nervous system drugmaker.
- The combined company will operate as Supernus and begin trading on the Nasdaq Global Market under SUPN on Nov. 3, 2026.
- Supernus holders received 1.5401 Indivior common shares per share, owning approximately 43.5% of the combined company; Indivior holders own approximately 56.5%.
- Indivior stockholders immediately before closing will receive a one-time special cash dividend totaling $1 billion.
- The dividend is funded through a $650 million Citibank term loan facility, with the remainder coming from existing combined-company cash.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
TotalEnergies says Iran war could accelerate energy transition
New Token Issuance for This Altcoin Could Drop by 36 Percent: Critical Vote Passes
US October ISM Manufacturing Index Expands Beyond Expectations, Output Growth Hits Strongest Level in Nearly Five Years
The Manufacturing Purchasing Managers' Index (PMI) released by the Institute for Supply Management (ISM) in the United States rose by 1 point in October to reach 55.5, marking the second highest reading in more than four years and exceeding the market expectation of 54.7. The production index recorded its best performance since the end of 2021, while the new orders index, a key indicator of demand, also reached its highest level since July.
Crypto prices
More
